

2nd Quarter 2024 Results¹

2nd Quarter 2024 Sales

Worldwide increased ▲
\$22.4B | **4.3%**

Excluding acquisitions /
 divestitures on an
 operational basis

Worldwide increased ▲
7.1%*²

Diluted earnings per share

Decreased ▼
\$1.93 | **(5.9)%**

Adjusted diluted earnings per share*

Increased ▲
\$2.82 | **10.2%**




Joaquin Duato
 Chairman & Chief
 Executive Officer
 Johnson & Johnson

“ Johnson & Johnson's second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and adjusted operational earnings per share growth. With a robust pipeline, upcoming regulatory milestones for RYBREVANT and TREMFYA, the integration of Shockwave, and continued expansion of newly launched products, including ACUVUE OASYS MAX 1-Day contact lenses and our VARIPULSE platform, we have a strong foundation for near and long-term growth. ”

\$14.5 billion **Worldwide Innovative Medicine sales**
 Innovative Medicine worldwide reported sales increased 6.5%² or 8.8%² operationally³.
 Primary operational drivers:



\$8.0 billion **Worldwide MedTech sales**
 MedTech worldwide reported sales increased 2.2% or 4.4% operationally³.
 Primary operational drivers:



For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson's earnings release issued July 17, 2024, available at <https://www.investor.jnj.com/financials/quarterly-results/default.aspx>

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

¹ Results have been recast to reflect the continuing operations of Johnson & Johnson.

² Excluding COVID-19 Vaccine.

³ Non-GAAP measure; excludes the impact of translational currency.

Note: Values may be rounded.

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on July 17, 2024, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.